Skip to content
Homepage
Author:
Sonoma Pharmaceuticals, Inc.
Posted Date:
June 30, 2026
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution
Sonoma Pharmaceuticals, Inc.
June 30, 2026
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
Sonoma Pharmaceuticals, Inc.
June 16, 2026
Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering
Sonoma Pharmaceuticals, Inc.
April 24, 2026
Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey’s Aquanil Brand for Sensitive Skin
Sonoma Pharmaceuticals, Inc.
March 18, 2026
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results
Sonoma Pharmaceuticals, Inc.
February 10, 2026
Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
Sonoma Pharmaceuticals, Inc.
January 28, 2026
